ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.

Shuo Ma, Andrew W. Roberts, Nikita Rudersdorf et al.|Journal of Clinical Oncology|2014

Cited by 22